Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 USD | +30.39% | +88.12% | -79.82% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 32.73 | 8.733 | 4.136 | 6.23 | - | - |
Enterprise Value (EV) 1 | 32.73 | 8.733 | 4.136 | 6.23 | 6.23 | 6.23 |
P/E ratio | - | - | - | - | - | - |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | -550,536 x | - | - | - | - |
FCF Yield | - | -0% | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 16.1 | 16.2 | 627 | 6,108 | - | - |
Reference price 2 | 2,032 | 538.4 | 6.592 | 1.020 | 1.020 | 1.020 |
Announcement Date | 3/31/22 | 3/31/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -6.151 | -18.67 | -19.42 | -14.7 | -22.1 | -33.1 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - |
Net income | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - |
EPS | - | - | - | - | - | - |
Free Cash Flow | - | -15.86 | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/31/22 | 3/31/23 | 4/1/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -2.986 | -4.707 | -4.954 | -5.527 | - | -5.131 | -5.328 | -4.059 | -3.2 | -3.4 | -3.8 | -4.3 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - |
Net income | - | - | - | - | -4.817 | - | - | - | - | - | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - |
EPS | - | - | - | - | -264.0 | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/31/22 | 8/15/22 | 11/14/22 | 3/31/23 | 5/15/23 | 8/14/23 | 11/14/23 | 4/1/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | -15.9 | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | 0.1 | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/31/22 | 3/31/23 | 4/1/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-79.82% | 6.23M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- RNAZ Stock
- Financials TransCode Therapeutics, Inc.